Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PGNY Stock Forecast 2026-2027
$26.63
Current Price
$2.09B
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PGNY Price Targets
+16.4%
To High Target of $31.00
+12.7%
To Median Target of $30.00
-2.4%
To Low Target of $26.00
PGNY Price Momentum
+3.0%
1 Week Change
+16.4%
1 Month Change
+26.6%
1 Year Change
+3.7%
Year-to-Date Change
-7.4%
From 52W High of $28.75
+65.4%
From 52W Low of $16.10
📊 TOP ANALYST CALLS
Did PGNY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Progyny is one of their latest high-conviction picks.
Latest PGNY Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PGNY has a bullish consensus with a median price target of $30.00 (ranging from $26.00 to $31.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $26.63, the median forecast implies a 12.7% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Cherny at B of A Securities, projecting a 16.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PGNY Analyst Ratings
10
Buy
1
Hold
0
Sell
PGNY Price Target Range
Low
$26.00
Average
$30.00
High
$31.00
Current: $26.63
Latest PGNY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PGNY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 2, 2026 | B of A Securities | Michael Cherny | Buy | Maintains | $31.00 |
| May 19, 2026 | Canaccord Genuity | Buy | Upgrade | $N/A | |
| May 18, 2026 | Barclays | Overweight | Maintains | $N/A | |
| May 11, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| May 11, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Mar 20, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Mar 11, 2026 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Mar 5, 2026 | BTIG | Buy | Maintains | $N/A | |
| Mar 2, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Mar 2, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Jan 20, 2026 | Citizens | Market Outperform | Upgrade | $N/A | |
| Jan 8, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Dec 9, 2025 | Barclays | Overweight | Initiates | $N/A | |
| Nov 17, 2025 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Nov 12, 2025 | Keybanc | Overweight | Upgrade | $N/A | |
| Nov 11, 2025 | JP Morgan | Neutral | Maintains | $N/A | |
| Aug 26, 2025 | JP Morgan | Neutral | Maintains | $N/A | |
| Aug 20, 2025 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Aug 8, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Jul 17, 2025 | Truist Securities | Hold | Maintains | $N/A |
Progyny Inc. (PGNY) Competitors
The following stocks are similar to Progyny based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Progyny Inc. (PGNY) Financial Data
Progyny Inc. has a market capitalization of $2.09B with a P/E ratio of 33.3x. The company generates $1.29B in trailing twelve-month revenue with a 5.2% profit margin.
Revenue growth is +1.4% quarter-over-quarter, while maintaining an operating margin of +10.8% and return on equity of +14.9%.
Valuation Metrics
Market Cap
$2.09B
Enterprise Value
$1.83B
P/E Ratio
33.3x
PEG Ratio
0.5x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
+1.4%
Gross Margin
+25.3%
Operating Margin
+10.8%
Net Margin
+5.2%
EPS Growth
+60.9%
Financial Health
Cash/Price Ratio
+10.8%
Current Ratio
2.1x
Debt/Equity
6.2x
ROE
+14.9%
ROA
+9.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Progyny Inc. (PGNY) Business Model
About Progyny Inc.
What They Do
Provides fertility and women's health benefits solutions.
Business Model
Progyny generates revenue by offering comprehensive fertility and family building benefits to employers, health plans, and benefit purchasers. Their data-driven approach enables them to deliver personalized care and support throughout various stages of family planning, which enhances member satisfaction and improves clinical outcomes, ultimately making their services more attractive to companies looking to provide valuable employee benefits.
Additional Information
Progyny boasts a network of NCQA-accredited women's health providers and supports multiple pathways to parenthood, including adoption and surrogacy. The company's focus on superior member experiences and cost efficiencies allows it to seamlessly integrate into existing benefit structures, appealing to diverse industries and promoting healthier family planning journeys.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
835
CEO
Mr. Peter Anevski CPA
Country
United States
IPO Year
2019
Website
www.progyny.comProgyny Inc. (PGNY) Latest News & Analysis
Latest News
New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System
16 days ago
Quick Summary
Patients prioritize human connection and advocacy in healthcare, indicating these factors are key to reducing stress and enhancing the overall care experience.
Why It Matters
Rising demand for human connection in healthcare may drive investment in companies focusing on patient experience, advocacy services, and innovative care models, potentially boosting their market value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Progyny, Inc. Announces Share Repurchase Program
18 days ago
Quick Summary
Progyny, Inc. (Nasdaq: PGNY) announced a $200 million share repurchase program, to be funded by available cash, enhancing shareholder value.
Why It Matters
Progyny's $200 million share repurchase signals confidence in its financial health, potentially boosting share value and signaling to investors strong future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Progyny, Inc. held a shareholder and analyst call to discuss its financial performance and strategic initiatives. Details on revenue, growth, and future outlook were addressed.
Why It Matters
The shareholder/analyst call for Progyny, Inc. provides insights into company performance, strategic direction, and financial health, crucial for evaluating investment potential and market sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Bull of the Day: Progyny (PGNY)
27 days ago
Quick Summary
Progyny (PGNY) is positioned as a healthcare disruptor with significant growth potential, making it an attractive option for growth investors.
Why It Matters
Progyny (PGNY) presents a compelling opportunity in the healthcare sector, driven by strong growth potential and favorable market trends, appealing to growth-focused investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
1 month ago
Quick Summary
Progyny, Inc. (PGNY) presented at the Bank of America Global Healthcare Conference 2026, highlighting its developments in the healthcare sector.
Why It Matters
Progyny's presentation at a major healthcare conference signals potential growth opportunities and investor interest, influencing stock performance and market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Progyny, Inc. (Nasdaq: PGNY) CEO Pete Anevski and CFO Mark Livingston will speak at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 11:20 AM PT / 2:20 PM ET.
Why It Matters
Leadership participation in a major healthcare conference signals potential insights into company strategy and performance, influencing investor sentiment and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PGNY Stock
What is Progyny Inc.'s (PGNY) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Progyny Inc. (PGNY) has a median price target of $30.00. The highest price target is $31.00 and the lowest is $26.00.
Is PGNY stock a good investment in 2026?
According to current analyst ratings, PGNY has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $26.63. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PGNY stock?
Wall Street analysts predict PGNY stock could reach $30.00 in the next 12 months. This represents a 12.7% increase from the current price of $26.63. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Progyny Inc.'s business model?
Progyny generates revenue by offering comprehensive fertility and family building benefits to employers, health plans, and benefit purchasers. Their data-driven approach enables them to deliver personalized care and support throughout various stages of family planning, which enhances member satisfaction and improves clinical outcomes, ultimately making their services more attractive to companies looking to provide valuable employee benefits.
What is the highest forecasted price for PGNY Progyny Inc.?
The highest price target for PGNY is $31.00 from Michael Cherny at B of A Securities, which represents a 16.4% increase from the current price of $26.63.
What is the lowest forecasted price for PGNY Progyny Inc.?
The lowest price target for PGNY is $26.00 from at , which represents a -2.4% decrease from the current price of $26.63.
What is the overall PGNY consensus from analysts for Progyny Inc.?
The overall analyst consensus for PGNY is bullish. Out of 2 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are PGNY stock price projections?
Stock price projections, including those for Progyny Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 1:51 AM UTC